How Are Emerging Therapies Enhancing HER2 Positive Breast Cancer Management
Understanding HER2-positive breast cancer is essential, as this aggressive subtype affects around 20% of breast cancer patients. Characterized by excessive HER2 protein, it prompts significant advancements in targeted therapy, including trastuzumab and pertuzumab. Testing HER2 status is critical for personalized treatment strategies. While HER2-positive cancers benefit from targeted treatments, ongoing research aims to address HER2-low […]
3 minute read